N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling

Yingying Shi, Mingxia Zhou, Junkai Yan, Zizhen Gong, Jin Wu, Yuanwen Chen, Yingwei ChenFrontiers in Pharmacology 2020 · DOI

TL;DR

This study reveals that the endogenous peptide N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) plays a protective role against intestinal inflammation, particularly in inflammatory bowel disease (IBD). The researchers found that AcSDKP levels are reduced in inflamed IBD tissues and that exogenous AcSDKP administration ameliorates experimental colitis in mice by inhibiting key inflammatory signaling pathways.

What Problem Does This Paper Address?

Inflammatory bowel disease (IBD), encompassing conditions like ulcerative colitis (UC) and Crohn's disease (CD), is characterized by chronic, relapsing inflammation of the gastrointestinal tract. While current treatments exist, they have limitations such as high cost, potential side effects, and loss of effectiveness. Therefore, there's a critical need for novel, safer, and more effective therapeutic strategies with well-understood mechanisms. The role of AcSDKP, a known immunomodulatory peptide with beneficial effects in cardiovascular and renal diseases, in the context of IBD was poorly understood, presenting a knowledge gap that this research aimed to fill.

Methods

The study employed a multi-pronged approach:

  • Human Tissue Analysis: Researchers analyzed colonic mucosal biopsies from patients with active ulcerative colitis (UC) and paired non-inflamed tissues. They used quantitative real-time PCR (qRT-PCR) to measure mRNA levels of key molecules involved in AcSDKP generation (thymosin β4 - Tβ4, meprin-α, prolyl endopeptidase - PREP) and degradation (angiotensin-converting enzyme - ACE). Immunohistochemistry was also used to visualize protein expression of Tβ4, meprin-α, and PREP.
  • In Vitro Cell Culture: Human colonic adenoma cells (Caco-2) were used to model intestinal inflammation. These cells were stimulated with tumor necrosis factor-alpha (TNF-α) to induce an inflammatory state. The effects of AcSDKP on the expression of pro-inflammatory cytokines and chemokines were assessed. Additionally, the study investigated AcSDKP's impact on key inflammatory signaling pathways, specifically the mitogen-activated protein kinase (MAPK) pathway, by examining the phosphorylation of MEK, ERK, JNK, and p38 using Western blotting.
  • In Vivo Animal Models:
    • PREP Knockout (PREP-KO) Mice: To investigate the role of reduced AcSDKP levels, PREP-KO mice, which have impaired AcSDKP generation, were used. These mice were subjected to dextran sulfate sodium (DSS)-induced colitis, a standard model for experimental colitis. Various parameters were assessed, including body weight loss, disease activity index (DAI), colon length, and histological damage.
  • Exogenous AcSDKP Administration: Wild-type (WT) mice were treated with exogenous AcSDKP via mini-osmotic pumps before and during DSS-induced colitis. This allowed researchers to assess the therapeutic potential of AcSDKP in mitigating colitis symptoms and inflammation. Similar parameters as in the PREP-KO study were evaluated, along with colonic AcSDKP levels.

Datasets

Not discussed in the paper. The study primarily utilized patient samples and established animal models of colitis.

Key Insights and Ideas

  • AcSDKP Deficiency in IBD: The study provides strong evidence that AcSDKP levels are significantly reduced in inflamed intestinal tissues of UC patients. This suggests that a compromised ability to generate AcSDKP might contribute to the heightened inflammation seen in IBD.
  • MEK-ERK Pathway as a Target: AcSDKP's anti-inflammatory action in intestinal epithelial cells appears to be mediated, at least in part, by inhibiting the MEK-ERK signaling pathway. This pathway is a crucial regulator of inflammatory responses, making it a promising target for therapeutic intervention.
  • PREP's Crucial Role in AcSDKP Generation: The study highlights the indispensable role of prolyl endopeptidase (PREP) in generating AcSDKP in the colon. Mice lacking PREP were more susceptible to DSS-induced colitis, underscoring the importance of AcSDKP for intestinal homeostasis.
  • Therapeutic Potential of AcSDKP: The administration of exogenous AcSDKP effectively attenuated the clinical and histological severity of experimental colitis in mice. This finding strongly supports the potential of AcSDKP as a therapeutic agent for IBD.

Key Results

  • Human Samples: mRNA levels of Tβ4 and meprin-α were significantly lower in inflamed UC mucosa compared to non-inflamed mucosa, while PREP levels were similar.
  • In Vitro: AcSDKP (at 100 nM) significantly inhibited the mRNA expression of pro-inflammatory cytokines (MCP-1, IL-8, TNF-α, IL-6) in TNF-α-stimulated Caco-2 cells. It also suppressed the phosphorylation of MEK and ERK, but not JNK or p38.
  • In Vivo (PREP-KO Mice): PREP-KO mice exhibited earlier and more pronounced weight loss, higher DAI scores, shorter colon lengths, and more severe histological damage compared to WT mice after DSS treatment.
  • In Vivo (Exogenous AcSDKP): AcSDKP infusion in WT mice significantly attenuated weight loss, reduced colon shortening, lowered DAI scores, and improved histological scores in DSS-induced colitis. It also led to reduced expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and decreased infiltration of neutrophils and macrophages in the colon.

Limitations and Future Work

The authors acknowledge several limitations:

  • Correlation vs. Causation: While they observed reduced AcSDKP in inflamed IBD tissues, measuring definite AcSDKP levels in a larger cohort is warranted to definitively establish its correlation with colitis severity.
  • Broader Signaling Pathways: AcSDKP might modulate other signaling pathways beyond MEK-ERK that contribute to inflammation. Further research is needed to explore these possibilities.
  • Acute vs. Chronic Colitis: The study focused on acute DSS-induced colitis. Future work should investigate AcSDKP's effects on chronic intestinal inflammation models.

Despite these limitations, the study strongly suggests that AcSDKP and its analogs, which are resistant to ACE degradation, hold significant promise for the treatment of IBD and other inflammatory diseases due to their inherent safety profile and demonstrated efficacy.

Summary updated

Abstract

N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous immunomodulatory peptide that is generated from thymosin β4 (Tβ4) through stepwise hydrolysis, involving meprin-α and prolyl endopeptidase (PREP). It is well acknowledged that AcSDKP exerts beneficial effects on multiple cardiovascular and renal diseases. However, the functional role of AcSDKP in inflammatory bowel disease (IBD) remains poorly understood. Here, we aimed to assess the content of AcSDKP in patients with IBD and investigate the impact of AcSDKP on intestinal inflammation in IBD. We found that in the inflamed mucosal specimens of patients with ulcerative colitis, the expression levels of Tβ4 and meprin-α were decreased, while PREP was expressed at similar levels to non-inflamed mucosa. <i>In vitro</i>, AcSDKP inhibited the expression of proinflammatory factors in intestinal epithelial cells partially by reducing the activation of MEK-ERK signaling. <i>In vivo</i> studies showed that transgenic mice, with lower levels of AcSDKP, were more vulnerable to dextran sulfate sodium (DSS)-induced colitis and exhibited more severe intestinal inflammatory responses. On the other hand, exogenous AcSDKP infusion significantly attenuated the clinical symptoms and intestinal mucosal inflammation in DSS-induced mice. In conclusion, results from this study demonstrated the anti-inflammatory function of AcSDKP within the intestine and suggest that AcSDKP has a promising therapeutic potential for IBD treatment.
BibTeX
@inproceedings{shi2020n,
  author = {Yingying Shi and Mingxia Zhou and Junkai Yan and Zizhen Gong and Jin Wu and Yuanwen Chen and Yingwei Chen and Yingwei Chen and Yingwei Chen},
  title = {{N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Mitigates Experimental Colitis Through Inhibition of Intestinal Mucosal Inflammatory Responses via MEK-ERK Signaling}},
  booktitle = {Frontiers in Pharmacology},
  year = {2020},
  doi = {10.3389/fphar.2020.00593},
}
Figure